Planned Solutions Inc. Takes Position in Novo Nordisk A/S (NYSE:NVO)

Planned Solutions Inc. acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,878 shares of the company’s stock, valued at approximately $194,000.

Other large investors have also made changes to their positions in the company. Chilton Capital Management LLC increased its holdings in Novo Nordisk A/S by 0.6% during the 2nd quarter. Chilton Capital Management LLC now owns 10,063 shares of the company’s stock worth $1,628,000 after purchasing an additional 63 shares in the last quarter. IHT Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. IHT Wealth Management LLC now owns 2,369 shares of the company’s stock worth $321,000 after buying an additional 80 shares during the last quarter. Hancock Whitney Corp boosted its stake in shares of Novo Nordisk A/S by 4.1% during the 1st quarter. Hancock Whitney Corp now owns 2,342 shares of the company’s stock worth $373,000 after buying an additional 92 shares during the last quarter. SRS Capital Advisors Inc. boosted its stake in shares of Novo Nordisk A/S by 9.6% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,060 shares of the company’s stock worth $169,000 after buying an additional 93 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after buying an additional 100 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $128.05 on Thursday. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The stock has a market cap of $574.63 billion, a price-to-earnings ratio of 47.34, a P/E/G ratio of 2.13 and a beta of 0.41. The company’s fifty day moving average is $121.34 and its 200 day moving average is $104.22.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.35 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Investors of record on Monday, March 25th will be issued a $0.664 dividend. This represents a dividend yield of 0.9%. The ex-dividend date is Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is currently 49.17%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, March 20th. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. TD Cowen upped their price target on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, December 4th. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $126.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.